Systemic therapy for superficial bladder cancer.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002278:Carcinoma in Situ / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005200:FANFT; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D051379:Mice; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011736:Pyridoxine / Q000008:administration & dosage / Q000009:adverse effects; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000188:drug therapy*; D014801:Vitamin A / Q000008:administration & dosage / Q000009:adverse effects
D000970:Antineoplastic Agents; D014801:Vitamin A; D005200:FANFT; D003520:Cyclophosphamide; D011736:Pyridoxine; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate